GlassScriptPhysician profile
William Edward Golding
NPI 1144006438
$7,456.71
in general payments reported to CMS, 2019-2025
23 companies · $4,454 in 2025
The $4,454 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,003 · 2025: $4,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,345 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,345.22 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,219.78 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $826.42 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $809.45 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $633.18 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $610.83 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $574.31 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $483.48 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $442.93 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $427.55 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $394.63 | 2024-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $230.87 | 2024-2025 | Wellbutrin, Aplenzin |
| Corium, LLC | $187.95 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $125.00 | 2024 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $111.36 | 2024-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $100.28 | 2024-2025 | Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $81.28 | 2024 | Brixadi |
| Acadia Pharmaceuticals INC | $53.55 | 2025 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $32.21 | 2024 | Quviviq |
| Neos Therapeutics, LP | $30.75 | 2025 | Adzenys Xr-Odt |
| Livanova USA, INC. | $22.24 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Ironshore Pharmaceuticals INC. | $19.93 | 2024 | |
| Astellas Pharma US INC | $19.75 | 2024 | Veozah |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.98 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Golding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.